アクセス数 : ?
ダウンロード数 : ?
ID 115665
タイトル別表記
PREDICTION SYSTEMS FOR BLADDER CANCER THERAPY
著者
Kato, Yoichiro Iwate Medical University
Zembutsu, Hitoshi National Cancer Center Research Institute
Takata, Ryo Iwate Medical University
Matsuura, Tomohiko Iwate Medical University
Kato, Renpei Iwate Medical University|University of Tokushima
Kanehira, Mitsugu Iwate Medical University
Iwasaki, Kazuhiro Iwate Medical University
Yamada, Noriyuki Iwate Medical University
Sugai, Tamotsu Iwate Medical University
Fujioka, Tomoaki Iwate Medical University
Nakamura, Yusuke University of Chicago
Obara, Wataru Iwate Medical University
キーワード
methotrexate
vinblastine
doxorubicin plus cisplatin
carboplatin plus gemcitabine
reverse transcription‑polymerase chain reaction
neoadjuvant chemotherapy
muscle invasive bladder cancer
資料タイプ
学術雑誌論文
抄録
The present study established systems to predict the chemo‑sensitivity of muscle invasive bladder cancer (MIBC) for neoadjuvant chemotherapy (NAC) with methotrexate, vinblastine, doxorubicin plus cisplatin (M‑VAC) and carboplatin plus gemcitabine (CaG) by analyzing microarray data. The primary aim of the study was to investigate whether the clinical response would increase by combining these prediction systems. Treatment of each MIBC case was allocated into M‑VAC NAC, CaG NAC, surgery, or radiation therapy groups by their prediction score (PS), which was calculated using the designed chemo‑sensitivity prediction system. The therapeutic effect of the present study was compared with the results of historical controls (n=76 patients) whose treatments were not allocated using the chemo‑sensitivity prediction system. In addition, the overall survival between the predicted to be responder (positive PS) group and predicted to be non‑responder (negative PS) group was investigated in the present study. Of the 33 patients with MIBC, 25 cases were positive PS and 8 were negative PS. Among the 25 positive PS cases, 7 were allocated to receive M‑VAC NAC and 18 were allocated to receive CaG NAC according to the results of the prediction systems. Of the 8 negative PS cases, 3 received CaG NAC, 1 received surgery without NAC and 4 received radiation therapy. The total clinical response to NAC was 88.0% (22/25), which was significantly increased compared with the historical controls [56.6% (43/76) P=0.0041]. Overall survival of the positive PS group in the study was significantly increased compared with the negative PS group (P=0.027). In conclusion, the combination of the two prediction systems may increase the treatment efficacy for patients with MIBC by proposing the optimal NAC regimen. In addition, the positive PS group would have a better prognosis compared with the negative PS group. These results suggest that the two prediction systems may lead to the achievement of ‘precision medicine’.
掲載誌名
Oncology Letters
ISSN
17921074
17921082
出版者
Spandidos Publications
16
5
開始ページ
5775
終了ページ
5784
発行日
2018-08-20
権利情報
This work is licensed under a Creative Commons Attribution 4.0 International (CC BY-NC 4.0) License(https://creativecommons.org/licenses/by-nc/4.0/)
EDB ID
出版社版DOI
出版社版URL
フルテキストファイル
言語
eng
著者版フラグ
出版社版
部局
先端酵素学研究所